What is the treatment for methotrexate toxicity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Methotrexate Toxicity: Treatment and Management

The treatment of methotrexate toxicity requires immediate administration of leucovorin (folinic acid) rescue, aggressive hydration with urinary alkalinization, and consideration of glucarpidase for severe cases with delayed elimination or renal dysfunction. 1, 2

Immediate Management of Methotrexate Toxicity

First-Line Interventions

  • Leucovorin (folinic acid) rescue:

    • Begin as promptly as possible after toxicity is identified
    • Effectiveness decreases as time interval between methotrexate administration and leucovorin initiation increases 1
    • Dosing: Start with high-dose leucovorin (100 mg/m²) for severe toxicity 2
    • Continue until serum methotrexate levels fall below 0.05 μmol/L 2
  • Aggressive hydration and urinary alkalinization:

    • Administer IV fluids at 3-4 L/m²/day 2
    • Maintain urinary pH >7.0 using sodium bicarbonate 1, 2
    • Prevents precipitation of methotrexate in renal tubules

For Severe Toxicity or Delayed Elimination

  • Glucarpidase (carboxypeptidase G2):
    • Indicated for toxic methotrexate concentrations with delayed clearance due to impaired renal function
    • Reduces plasma methotrexate levels by up to 86% 2
    • Do not administer leucovorin within 2 hours before or after glucarpidase (leucovorin is a substrate for glucarpidase) 1

Monitoring During Treatment

  • Serum methotrexate levels:

    • Measure at 24,48, and 72 hours after start of infusion
    • Continue daily measurement until levels <0.05 μmol/L 2
    • Adjust leucovorin dose based on these levels
  • Laboratory monitoring:

    • Complete blood count (CBC)
    • Serum creatinine and renal function
    • Liver transaminases
    • Continue monitoring until normalization 2

Management Based on Specific Toxicities

Renal Toxicity

  • Methotrexate crystallizes in renal tubules causing acute kidney injury (AKI) in 2-12% of patients 3
  • Management:
    • Increase hydration and urinary alkalinization
    • Higher doses of leucovorin
    • Consider glucarpidase if significant renal dysfunction (eGFR <30 mL/min) 4
    • Avoid nephrotoxic medications

Hematologic Toxicity

  • Risk factors: renal insufficiency, advanced age, dosing errors, drug interactions, hypoalbuminemia 5
  • Management:
    • Continue leucovorin until recovery
    • Consider growth factors for severe neutropenia
    • Monitor for infections and provide prophylactic antibiotics if indicated

Hepatotoxicity

  • More common in patients with obesity, diabetes, hyperlipidemia, and non-alcoholic fatty liver disease 5
  • Management:
    • Continue leucovorin
    • Monitor liver function tests until normalization
    • Avoid other hepatotoxic agents including alcohol, statins, and retinoids 5

Mucositis and Gastrointestinal Toxicity

  • Management:
    • Supportive care with oral hygiene
    • Pain management
    • Nutritional support
    • Continue leucovorin until resolution

Special Considerations

Overdose Management

  • If ingestion occurred within 1 hour, administer activated charcoal 2
  • For extreme cases with very high levels, consider hemodialysis although evidence suggests it may not significantly improve elimination compared to glucarpidase 6
  • The EXTRIP workgroup suggests against extracorporeal treatments when standard care is provided, especially when glucarpidase is administered 6

Prevention of Future Toxicity

  • Identify risk factors: renal dysfunction, drug interactions, MTHFR gene mutations 2
  • Consider folic acid supplementation (1-5 mg daily except on methotrexate day) 2
  • Enhanced monitoring for patients with risk factors
  • Dose adjustment based on renal function (50% reduction if eGFR 20-50 mL/min, contraindicated if <20 mL/min) 2

Common Pitfalls to Avoid

  • Delaying leucovorin administration (effectiveness decreases with time)
  • Inadequate hydration and urinary alkalinization
  • Failure to monitor methotrexate levels and adjust leucovorin accordingly
  • Concurrent administration of drugs that interact with methotrexate (salicylates, NSAIDs, penicillins, probenecid, sulfonamides) 5
  • Administering leucovorin within 2 hours of glucarpidase

High-dose leucovorin as sole therapy has been shown to be effective for managing methotrexate toxicity in patients with high methotrexate levels, with tolerable morbidity and without the need for extracorporeal removal in many cases 7.

References

Guideline

High-Dose Methotrexate Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

High-dose leucovorin as sole therapy for methotrexate toxicity.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.